Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

• Main Authors: Nastya Kassir (Author), Rui Zhu (Author), Anita Moein (Author), Jurgen Langenhorst (Author), Jakob Ribbing (Author), Rong Zhang (Author), Meina T. Tang (Author), Young S. Oh (Author), Wenhui Zhang (Author)
• Format: Book
• Published: Wiley, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Etrolizumab is an IgG1‐humanized monoclonal anti‐β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately‐to‐severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibito...